[Local use of aprotinin in neurosurgical operations for the prevention of hyperfibrinolytic hemorrhage].
The local use of a commercial solution of the proteinase inhibitor aprotinin (Trasylol) prevents a premature fibrinolysis which may lead to post-operative hyperfibrinolytic bleeding. Among 1.236 neurosurgical patients in whom aprotinin was routinely locally applied there were 8 cases of post-operative bleeding (0,6%). In 7 of these cases an impaired coagulation had been previously found or was found during surgery. The intra-operative use of Trasylol appears to be suited to reduce the rate of post-operative haemorrhagic complications in neurosurgery.
D000328:Adult; D000368:Aged; D007611:Aprotinin / Q000627:therapeutic use*; D001927:Brain Diseases / Q000097:blood / Q000601:surgery*; D001930:Brain Injuries / Q000097:blood / Q000601:surgery; D002543:Cerebral Hemorrhage / Q000097:blood / Q000517:prevention & control*; D002648:Child; D005260:Female; D005342:Fibrinolysis / Q000187:drug effects*; D006801:Humans; D008297:Male; D008875:Middle Aged
D007611:Aprotinin
Lokale Anwendung von Aprotinin bei neurochirurgischen Operationen.